BiotechTube

Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Cirrhosis

Conditions

Liver Cirrhosis

Trial Timeline

Oct 31, 2022 → Jul 17, 2025

NCT ID
NCT05516498

About Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin

Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin is a phase 2 stage product being developed by AstraZeneca for Liver Cirrhosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05516498. Target conditions include Liver Cirrhosis.

What happened to similar drugs?

20 of 20 similar drugs in Liver Cirrhosis were approved

Approved (20) Terminated (3) Active (0)
✅Advagraf + Prograf + PrografAstellas PharmaApproved
✅Prograf + AdvagrafAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
✅Advagraf + PrografAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅tacrolimus + mycophenolate mofetil + PrednisoneAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05516498Phase 2Terminated

Competing Products

20 competing products in Liver Cirrhosis

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
29
GODEX + PlaceboCelltrionPhase 3
47
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
TacrolimusAstellas PharmaPre-clinical
26
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
Advagraf + Prograf + PrografAstellas PharmaApproved
43
Prograf + AdvagrafAstellas PharmaApproved
43
ADVAGRAF®Astellas PharmaApproved
43
Prograf + MR4Astellas PharmaPhase 3
40
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 3
40
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
40
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
40
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
43
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
40
FK778Astellas PharmaPhase 2
35
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
40
Advagraf + PrografAstellas PharmaApproved
39